[go: up one dir, main page]

EP1846029A2 - Des adjuvants pour la vaccination etant le pam3cys, poly(i:c), imiquimod, loxoribine, r-848 et le cpg-dna, combine avec des epitopes du chm i ou chm ii - Google Patents

Des adjuvants pour la vaccination etant le pam3cys, poly(i:c), imiquimod, loxoribine, r-848 et le cpg-dna, combine avec des epitopes du chm i ou chm ii

Info

Publication number
EP1846029A2
EP1846029A2 EP05797932A EP05797932A EP1846029A2 EP 1846029 A2 EP1846029 A2 EP 1846029A2 EP 05797932 A EP05797932 A EP 05797932A EP 05797932 A EP05797932 A EP 05797932A EP 1846029 A2 EP1846029 A2 EP 1846029A2
Authority
EP
European Patent Office
Prior art keywords
pharmaceutical preparation
mammal
administration
toll
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP05797932A
Other languages
German (de)
English (en)
Inventor
Hansjörg Schild
Tobias Warger
Markus Radsak
Gerd Rechtsteiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johannes Gutenberg Universitaet Mainz
Original Assignee
Johannes Gutenberg Universitaet Mainz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johannes Gutenberg Universitaet Mainz filed Critical Johannes Gutenberg Universitaet Mainz
Publication of EP1846029A2 publication Critical patent/EP1846029A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Definitions

  • the present invention relates to a pharmaceutical preparation comprising at least one Toll-like receptor ligand and at least one peptide.
  • the invention also relates to the use of such a pharmaceutical preparation and also relates to a vaccination method.
  • the adaptive immune system plays an important role in the immune defense against certain microorganisms, for example viruses, certain fungi and bacteria, as well as in the detection and rejection of malignant (degenerate) cells (tumor cells). This will be sick, d. H. Virus-infected or malignant cells specifically recognized and eliminated by so-called cytotoxic T cells (CTL).
  • CTL cytotoxic T cells
  • a necessary prerequisite for recognition of the diseased cells by the cytotoxic T cells is the interaction of the T cell receptor (T cell receptor) of the cytotoxic T cells with a major histocompatibility complex I (major histocompatibility complex I; MHC I).
  • MHC class I molecules protein fragments (peptides consisting of 8 to 10 amino acids, so-called MHC class I ligands) are presented on the cell surface. These are then specifically recognized by a T cell receptor (TCR). MHC class I ligands are generated in each cell by enzymatic degradation and presented on the cell surface (so-called self-peptides). Virus-specific or tumor-specific self-peptides are also presented on virus-infected cells or malignant cells. Such cells can thus be recognized and destroyed by cytotoxic T cells (CTL) with a virus-specific or tumor-specific T cell receptor.
  • CTL cytotoxic T cells
  • CTL cytotoxic T cells
  • STL cytotoxic T cells
  • T cell receptor MHC I self-peptides
  • CTL In order to prevent the damage of healthy cells, which also present self-peptides, by cytotoxic T cells (CTL), in addition to the specific interaction between T cell receptor and MHC I self-peptide, CTL must be supplemented by additional co-potentials. stimulatory signals are first activated, so that they can then recognize and destroy their target cells (virus-infected cells or tumor cells). Without prior activation, a cytotoxic T cell (CTL) can not recognize and destroy the target cell via its specific self-peptides, despite its specific T cell receptor specific for a particular (eg virally infected or malignant) cell.
  • CTL cytotoxic T cell
  • cytotoxic T cells which have specific receptors for self-peptides presented on cells are incorrectly activated, for example in the context of an infection, this can lead to reactions of cytotoxic T cells against cells of healthy tissue.
  • the regulation of the activation of cytotoxic T cells is thus of central importance for whether a specific immune response is initiated or not.
  • Antigen-presenting cells are specialized cells which very efficiently take up and present antigens (for example viruses or bacteria). Examples are dendritic cells (DC) or the Langerhans cells in the skin. In the presence of danger signals, DCs mature, leading to an upregulation of co-stimulatory signals In this situation, the recognition of antigens leads to the activation of cytotoxic T cells (CTL) and to the initiation the immune response.
  • CTL cytotoxic T cells
  • TLR toll-like receptors
  • Dendritic cells can be of a different nature, for example from activated T-helper cells or also directly from pathogens. If the "danger signals" of pathogens stem from pathogens, for example Recognition of certain conserved structures of viruses, bacteria or fungi, through which Toll-like receptors take place.
  • TLRs Toll-like receptors
  • LPS lipopolysaccharides
  • WO-A 01 / 015,698 and WO-A 045,494 disclose the recognition of various viral structures which occur in connection with human and animal diseases of viral origin by TLR7, ie the substance imiquimod ⁇ 1- (2-methylpropyl) 1 H-imidazo [4,5-c] chi-nolin-4-amine ⁇ .
  • Tumor immunology encompasses a wide field of biological phenomena which include the interaction of malignant degenerate cells with the innate and adaptive immune system.
  • T cells play a central role, as they can specifically recognize and eliminate tumor cells. Since most of the tumor-associated proteins are intracellular, T cells are apparently the most suitable tool to elicit a tumor-specific immune response. Namely, antibodies can not enter the cell, and innate immune cells lack the high specificity of T cells.
  • cytotoxic T cells which eliminate only diseased cells but spare healthy ones, is an attractive target.
  • Adotevi and WH Fridman Synthetic and natural non-live vectors: rational for their clinical development in Cancer Vaccine protocols; Vaccine, December 19, 2002: 20 (Suppl. 4), A 32-39 ";” R. Edelmann; Adjuvants for the Future, in: MM Levine, GC Woodrow, JB Kaper, GS Cobon (ed.), New Generation Vacines, Volume 2, New York, Marcel Dekker (1997), 173-192) "; and "S. Agrawal, ER Kandimalla; Modulation of Toll-like Receptor 9 responses by synthetic immunostimulatory motifs of DNA; Ann. NY Acad. Be. 2003 (Dec.): 1002, 30 - 42.
  • T cells Due to the importance of T cells for the elimination of intracellular pathogens and tumor cells, recent immunization strategies attempt to address T cells, in particular cytotoxic T cells, which would also open up the possibilities of therapeutic vaccinations. All previous vaccination strategies have in common that they function reasonably well in practice, so that, for example, cytotoxic T cells can be measurably activated in patients and their number can be increased. However, the methods are only moderately good able to generate efficient T cell responses, in particular to achieve sufficient tumor rejection. In addition, the known vaccination methods are still associated with significant side effects up to toxicity ["E. Tartour et al., Loc. Cit. ", And” R. Edelmann, loc. Cit. "]. Namely, it is known from animal models that immunizations with CpG-DNA have side effects which considerably limit the use of this adjuvant. In addition, especially the DC-based methods are associated with an effort that can not be transferred into everyday hospital practice or everyday practice.
  • the object of the invention was to contribute to a significantly improved generation of cytotoxic T cells by an efficient activation, without causing the disadvantages of the prior art occur.
  • activation of Toll-like receptors should efficiently achieve the activation of antigen-presenting cells.
  • Another object of the invention was to show a way to non-invasive Auslö ⁇ solution of a systemic, T-cell-mediated immune response.
  • Yet another object of the invention was to provide an inexpensive vaccine concept for the generation of cytotoxic T cells that is inexpensive and requires only little technical effort.
  • Yet another object of the invention was to provide preparations for novel immunological-based preventive and therapeutic methods against a broad spectrum of diseases, including diseases or tumors induced by viruses or bacteria.
  • topically administrable preparations which have the necessary T-cell receptor-specific peptides tid-signal substances together with a ligand for a toll-like receptor, non-invasively capable of triggering a systemic T-cell-mediated immune response by generating specific cytotoxic T cells in the Location are.
  • This demonstrates a simpler, faster, and more efficient way to induce immune responses to any T cell antigen.
  • the invention thus relates to a pharmaceutical preparation which comprises at least one Toll-like receptor ligand, at least one peptide and optionally one or more substance (s) from the group carriers, excipients and additives.
  • Preferred embodiments of the pharmaceutical preparation result from the subclaims 2 to 10.
  • the invention also relates to the use of a pharmaceutical preparation as described in detail hereinafter for the prophylaxis and / or therapy of diseases induced by viruses and / or bacteria and / or fungi in a mammal or for the production of a medicament for prophylaxis and / or therapy of diseases induced by viruses and / or bacteria and / or fungi in a mammal.
  • the invention also relates to the use of a pharmaceutical preparation as described in detail below for the prophylaxis and / or treatment of diseases caused by excessive cell proliferation in a mammal or for the production of a medicament for the prophylaxis and / or treatment of excessive cell proliferation. Proliferation-related diseases in a mammal.
  • the invention also relates to methods for the prophylaxis and / or therapy of diseases induced by viruses and / or bacteria and / or fungi in a mammal or for the prophylaxis and / or treatment of diseases caused by excessive cell proliferation, which involve the administration of a pharmaceutically preparation according to the following detailed description to the mammal in an effective for the prophylaxis and / or treatment of said diseases concentration of the pharmacologically active Kom ⁇ components.
  • the invention also relates to a method for the prophylactic and / or therapeutic activation of the adaptive immune system of a mammal, which comprises administering to the mammal a pharmaceutical preparation as described in detail below for prophylactic and / or therapeutic activation of the mammalian subject
  • a method for the prophylactic and / or therapeutic activation of cytotoxic T cells of the immune system of a mammal which comprises administering a pharmaceutical preparation as described in detail below to the mammal in a mammalian immune system for the prophylactic and / or therapeutic activation of the cytotoxic T cells effective concentration of the pharmacologically effective men components comprises.
  • compositions according to the invention comprise as an essential component at least one Toll-like receptor ligand (TLR ligand).
  • TLR ligands in the present description and in the claims mean those compounds of natural and / or synthetic origin which are recognized by at least one Toll-like receptor and which promote the immune response Signals are useful.
  • the Toll-like receptor ligand (s) which can be used according to the invention can be natural or synthetic or synthetically modified natural compound (s).
  • the Toll-like receptor ligand (s) may be synthetic substances.
  • the previously known Toll-like receptor ligands are divided into groups of the compounds recognized by the respective Toll-like receptors TLR1, TLR2, TLR3, TLR4, etc.
  • Toll-like receptors So far 11 Toll-like receptors (up to TLR11) are known.
  • the ligands are commonly referred to as TLR1 ligands, TLR2 ligands, TLR3 ligands, TLR4 ligands, etc., to TLR11 ligands.
  • TLR1 ligands TLR1 ligands
  • TLR2 ligands TLR2 ligands
  • TLR3 ligands TLR3 ligands
  • TLR4 ligands etc.
  • the invention relates to a pharmi ⁇ cal preparation in which the at least one Toll-like receptor ligand is selected from TLR2 ligand, TLR3 ligand, TLR7 ligand, TLR8 ligand and TLR9 ligand.
  • a TLR7 ligand is used according to the invention.
  • the pharmaceutical preparation comprises at least one, more preferably exactly one Toll-like receptor ligand selected from the group consisting of compounds of natural and / or synthetic origin, which is derived from at least one Toll-like Re ⁇ zeptor be recognized and for triggering one or more the immune response promotional signals (s) are useful.
  • the term "natural and / or synthetic origin” is understood to mean that the compounds suitable as ligands of at least one toll-like receptor are either a compound also naturally occurring as a toll-like receptor ligand or an artificially synthesized compound Ligand, however, any suitable compound or a naturally occurring but synthetically modifying compound is (for example-but not exclusively-one of the compounds as described in the document WO-A 00/040228), or a naturally occurring as Toll-like receptor ligand as described above, which modifies chemically For example, it has been substituted or otherwise derivatized.
  • the at least one Toll-like receptor ligand is selected from the group consisting of Pam3Cys, poly (I: C), imiquimod, loxoline, R-848 and CpG DNA.
  • the Toll-like receptor ligand is imiquimod.
  • the compound known per se under the name "imiquimod” has the chemical name 1 - (2-methylpropyl) -1H-imidazo [4,5-c] quinolin-4-amine.
  • the pharmaceutical preparation comprises at least one peptide.
  • Suitable peptides are synthetic and / or natural peptides. According to the invention, “synthetic and / or natural” is understood to mean that the peptide is either a naturally occurring peptide or an artificially synthesized peptide which is nevertheless suitable according to the invention or a naturally occurring but synthetically modified peptide
  • synthetic and / or natural is understood to mean that the peptide is either a naturally occurring peptide or an artificially synthesized peptide which is nevertheless suitable according to the invention or a naturally occurring but synthetically modified peptide
  • it is also possible to use two or more peptides The use of a single peptide is preferred according to the invention because of the specificity of the signal triggering.
  • the at least one peptide is selected from major histocompatibility complex class I ligand, major histocompatibility complex class II ligand and other peptides containing these ligands.
  • Such peptides are furthermore preferably antigens for recognition by cytotoxic T cells and are even more preferably peptides of viral or bacterial origin or tumor antigens. specific peptides or tumor-associated peptides. These can be presented by MHC class 1 molecules as well as MHC class II molecules.
  • the pharmaceutical preparations according to the invention may optionally also contain one or more substances from the group of carriers, auxiliaries and additives.
  • these include, by way of example, without limiting the invention to this, one or more substances from the group Group hydrophilic and lipophilic Lö ⁇ sungsstoff, solubilizing agents, emulsifiers, viscosity adjusting agents, pH adjusting agents, chelating agents, preservatives, means for providing a basis for topical application (ointment and / or Cream bases), means for increasing the Penetrations ⁇ assets of the skin, etc ..
  • auxiliaries and additives isostearic acid, benzyl alcohol, cetyl alcohol, stearyl alcohol, white petrolatum, polysorbate 80 R , sorbitan stearate, glycerol, methyl 4-hydroxybenzoate, propyl 4-hydroxybenzoate, xanthan gum, purified water.
  • the amounts of the essential components contained in the pharmaceutical preparation according to the invention which is prophylactically and / or therapeutically effective in a specific situation depends on various factors, such as For example, the activity of the specific combination of at least one a Toll-like receptor ligand and at least one (synthetic) peptide, the route of administration, the frequency of administration, the specific formulation, the disease state to be treated and the constitution of the mammal or patient to be treated. Experts with expertise in this technical field can conveniently determine effective amounts in the individual case on the basis of some orienting experiments and the information contained in the present description.
  • prophylactically and / or therapeutically effective amount in the present description and in the claims means the amount of the combination of the two essential components (optionally several compounds of the two respective components Toll-like receptor ligand or synthetic Peptide) which is sufficient to induce a prophylactic effect and / or a therapeutic effect, for example a prophylactic and / or therapeutic effect in the prophylaxis and / or therapy of a particular disease, for example an inflammatory disease or disease caused by viruses or bacteria or the like or in the prophylaxis and / or therapy of a disease or tumor disease caused by excessive cell proliferation
  • a prophylactically and / or therapeutically effective amount is also an amount sufficient to provide the adaptive immune system of a mammal prophylactic and / o to therapeutically activate, or an amount which is sufficient to prophylactically and / or therapeutically activate cytotoxic T cells of the immune system of a mammal.
  • Preference according to the invention is given to pharmaceutical preparations which comprise at least one Toll-like receptor ligand in an amount of from 0.1 to 10% by weight; at least one peptide in an amount of 0.01 to 30% by weight; and one or more substance (s) from the group carriers, excipients and additives in a total amount of 0.1 to 99.9 wt .-%, each based on the total weight of the pharmaceutical preparation.
  • compositions according to the invention which include: at least one Toll-like receptor ligand in an amount of 1 to 10 wt .-%; at least one peptide in an amount of 0.1 to 5 wt%; and one or more substance (s) from the group carriers, excipients and additives in a total amount of 0.5 to 99 wt .-%, each based on the total weight of the pharmaceutical preparation.
  • a particular exemplary pharmaceutical preparation which does not limit the invention comprises at least one Toll-like receptor ligand in an amount of 1 to 5% by weight; at least one peptide in an amount of 0.2 to 2% by weight; and one or more substance (s) from the group carriers, excipients and additives in a total amount of 93 to 99 wt .-%, each based on the total weight of the pharmaceutical preparation.
  • the pharmaceutical preparation according to the invention comprises the at least one toll-like receptor ligand and the at least one peptide in a formulation for joint administration and action.
  • the two essential components are contained in a common formulation, ie they are administered together and can then jointly develop a prophylactic and / or therapeutic effect. In addition to the simple administration, this also permits precise dosing of the two components.
  • Conceivable examples of such pharmaceutical preparations according to the invention are - without the invention being limited thereto - solutions or suspensions for intraperitoneal administration, creams or ointments for a topical one , z.
  • a particularly preferred embodiment of such a pharmaceutical preparation according to the invention is a formulation suitable for topical administration.
  • a particularly illustrative, but not limiting example of such a preparation is an ointment, cream, solution or suspension for topical, ie epidermal, administration, for example for topical administration of the preparation to the skin of the mammal.
  • a commercially available cream is used which contains 5% of the Toll-like receptor ligand imiquimod in a conventional cream base (Aldara R , company 3M).
  • a particularly preferred example of a pharmaceutical preparation according to the present invention is one for the topical administration of a component and for the non-topical, preferably the subcutaneous or intradermal administration of one other component suitable for the joint action.
  • This embodiment has the advantage that the respective components can be administered by the respective administration route, which guarantees their best possible joint action in the mammal to be treated.
  • a still further preferred embodiment of the invention is a pharmaceutical preparation in a topical administration least Toll-like receptor ligand and a non-topical, preferably subcutaneous or intradermal administration of at least one peptide with the aim ( and the result) of the common action suitable formulation.
  • the at least one, more preferably the Toll-like receptor ligand is formulated in the form of a cream which can be administered epidermally, while the at least one peptide is formulated in the form of a solution or suspension, which are administered subcutaneously or intradermally can.
  • the invention also relates to uses of a pharmaceutical preparation as described in detail above. Such uses are in the fields
  • Prophylaxis and / or therapy of viruses and / or bacteria and / or fungus-induced diseases of a mammal Prophylaxis and / or therapy of viruses and / or bacteria and / or fungus-induced diseases of a mammal;
  • Prophylaxis and therapy of diseases caused by excessive cell proliferation such as tumor diseases of a mammal;
  • a medicament for the prophylaxis and therapy of diseases caused by exzensive cell proliferation such as tumor diseases of a mammal.
  • the use according to the invention of the pharmaceutical preparation is particularly advantageous in the prophylaxis and / or treatment of inflammatory diseases, more preferably in the prophylaxis and / or treatment of diseases caused by viral or microbial pathogens, while according to the invention a use of the pharmaceutical preparations in diseases caused by exz zessive cell proliferation and especially in tumor diseases is particularly preferred.
  • any mammals can be treated. Examples are mice, rats, guinea pigs, cats, dogs, monkeys and humans. In particularly preferred embodiments of the use of the pharmaceutical preparations according to the invention, the treated mammal is a human.
  • the pharmaceutical preparation is used by topical application of the pharmaceutical preparation, more preferably by way of epidermal administration, that is to say the application of the pharmaceutical preparation to the skin of the mammal.
  • an epidermal pharmaceutical preparation comprises both at least one Toll-like receptor ligand and at least one peptide in one phase for joint action on the body through the skin of the mammal. It has been found according to the invention surprisingly that in this way a rapid absorption of the active ingredients through the skin can be achieved and subsequently generates an efficient specific immune response of the cytotoxic T cells and thus a reliable detection and elimination of diseased cells from the Mammalian body can be initiated.
  • Another, likewise preferred use of the pharmaceutical preparation according to the invention is carried out by means of the separate topical application of one component and non-topical, preferably subcutaneous or tradermal, application of another component with the aim and result of a joint effect. This is even more preferably done by means of the topical application of a component to the skin of the mammal and the subcutaneous or intradermal application of another component which takes place immediately before or after or simultaneously with the topical application, wherein surprisingly a common action occurs.
  • a formulation comprising at least one toll-like receptor ligand is administered topically (eg epidermally) and comprises at least one peptide such as an MHC class I ligand Formulation shortly before or after the topical application of the other Kom ⁇ component or substantially simultaneously with this non-topically, for example, subcutaneously or intradermally, is applied, (wherein the reverse order can be selected), a common effect of the two Components Toll-like receptor ligand and MHC class I ligand in so far as - as in the common administration of both components in a preparation in the same application route - in the skin antigen-presenting cells bind and present the MHC class I ligand and simultaneously stimulated by the Toll-like receptor ligand to mediate latorischer signals are stimulated.
  • the invention also relates to a method for the prophylaxis and / or therapy of diseases induced by viruses and / or bacteria and / or fungi in a mammal, which comprises administering to the mammal, in a prophylactic manner, a pharmaceutical preparation according to the above detailed description and / or therapy of said diseases comprises effective concentration of the pharmacologically active components.
  • the invention also relates to a method for the prophylaxis and / or therapy of diseases caused by excessive cell proliferation (in particular tumor diseases) in a mammal, which comprises administering to the mammal a pharmaceutical preparation according to the above detailed description a concentration of the pharmacologically active components effective for the prophylaxis and / or therapy of said diseases.
  • the invention furthermore relates to a method for the prophylactic and / or therapeutic activation of the adaptive immune system of a mammal, which comprises administering a pharmaceutical preparation according to the detailed description to the mammal in a prophylactic and / or therapeutic activation of the immune system of the mammal effectively comprises concentration of the pharmacologically active components.
  • the invention also relates to a method for the prophylactic and / or therapeutic activation of cytotoxic T cells of the immune system of a mammal, which comprises administering a pharmaceutical preparation according to the above detailed description to the mammal in a prophylactic and / or therapeutic activation of the cytotoxic T cells comprises effective concentration of the pharmacologically active components.
  • prophylactic refers to a treatment or effect of a treatment of the mammalian body of preventive character, that is, with the aim of achieving a treatment Illness does not come to the outbreak. This excludes the cases in which a treatment is taken preventively in order to prevent the onset of the disease for the first time, such as also the cases in which a treatment is followed by a preventive measure in order to prevent a re-entry of a disease after previously successful therapy and healing for the umpteenth time.
  • therapy refers to a treatment or effect of a treatment of the mammalian body in the case of an already outbreak of a disease for the latter and / or complete cessation, adjusting a healthy state of the body of the mammal.
  • a prophylactic activation of the adaptive immune system or a prophylactic activation of cytotoxic T cells is understood as an activation intended to prevent the development of a disease, while the corresponding therapeutic activation is the rapid and / or complete termination of an already outbreak of the disease serves.
  • the present invention preferably relates to the therapeutic component, i. H. the rapid reaction to a currently occurring disease state involving the mammalian immune system.
  • the treatment involves the administration of a pharmaceutical preparation according to the invention as described in detail above to a mammal as an essential step, optionally after or before other steps of the method, the same Prophylaxis and / or therapy goal.
  • the administration can be effected by any desired route, without the invention being restricted to a particular route.
  • an intraperitoneal, intravenous, intramuscular, subcutaneous or intradermal, topical (eg epidermal), oral, intranasal, etc. administration are possible.
  • preference is given to a method in which the administration of the pharmaceutical preparation takes place by a topical route, more preferably wherein the pharmaceutical preparation is applied to the skin of the mammal, in particular of man. This route of administration opens up the possibility of generating an efficient specific immune response with activation of the cytotoxic T cells in a simple manner that is surprising for the person skilled in the art.
  • Another, likewise preferred embodiment of the invention relates to a method in which the administration of a part of the pharmaceutical preparation with at least one component is carried out by topical route and the administration of at least one other part of the pharmaceutical preparation with another component to non- topical, preferably by subcutaneous or intradermal route to the target and with the result ei ⁇ ner joint effect.
  • This can even more preferably take place in the manner that the administration of a part of the pharmaceutical preparation with at least one component is carried out by application to the skin of the mammal and the administration of another part of the pharmaceutical preparation with at least one other component
  • Subcutaneous or intradermal administration to the mammal is carried out immediately or before or after or simultaneously with the application to the skin, with the aim and with the result of joint action.
  • the components in particular which of the essential components of the pharmaceutical preparation according to the invention is administered topically and which of the essential components of the pharmaceutical preparation according to the invention are administered non-topically, for example (but not limited) subcutaneously or intradermally, since activation of the adaptive immune system can be achieved with the method according to the invention on independent routes of administration of the individual components of the preparation.
  • the administration of a part of the preparation which at least one Toll-like receptor ligand is carried out by topical application to the skin and the administration of another part of the preparation comprising at least one peptide is carried out by means of subcutaneous or intradermal administration.
  • the procedure of the invention the two application steps are performed either simultaneously or immediately sequentially, since the goal is the joint effect of both components, which is surprisingly achieved in practice, even if the routes of administration are different.
  • the order is not restricted according to the invention, but it is preferred if the topical (epidermal) administration of the Toll-like receptor ligand takes place immediately after the non-topical (for example subcutaneous or intradermal) administration of the peptide, for example of the MHC class I ligands.
  • the immunization of the mammal or the human patient achieved by the application of the components of the pharmaceutical preparation in common or in succession is optionally repeated several times, it being possible to choose any time interval between the treatments, but preferably a time of at least 24 h ⁇ two applications is located. This has the advantage that the efficiency of the treatment is significantly increased and at the same time side effects are minimized.
  • the amounts of the pharmaceutical preparation which are administered according to the invention are freely selectable by the person skilled in the art and are not subject to any restrictions. However, it has been found to be practical to use the pharmaceutical preparations, given as a single-dose dose, in an amount ranging from 0.1 to 100 mg of the preparation per kg of body weight of the mammal to be treated, more preferably in an amount in the range of 0.1 to 10 mg of the preparation per kg of body weight of the mammal to be treated and even more preferably in an amount in the range of 0.1 to 1 mg of the preparation per kg of body weight of sunu ⁇ gers to be treated. It is also possible according to the invention to specify the amounts as amounts of preparation per surface of the body of the mammal to be treated.
  • the amounts are then in preferred embodiments of the invention 0.1 to 500 mg of the preparation per 50 to 250 cm 2 body surface of the mammal to be behan ⁇ , more preferably 0.1 to 100 mg of preparation per 10 to 50 cm 2 body surface, even more preferably 0.1 to 5 mg of preparation per 4 to 10 cm 2 body surface of the mammal to be treated.
  • the treatment may - as stated above - be repeated one or more times with the same or slightly different amounts from the aforementioned amounts.
  • mice which codes for a specific T-cell receptor which has a specific MHC class I ligand (SGPSNTPPEI, abbreviated SGP) from the adenovirus type 5 in the context of MHC class I (FIG. H2-D b ) detects.
  • SGPSNTPPEI specific MHC class I ligand
  • the cytotoxic T cells (CTL) from these animals were only then activated when b with this MHC class I ligand SGP in the context of H2 D come into contact.
  • CTL cytotoxic T cells
  • the non-activated (“naive") CTL from transgenic donor mice were injected intravenously (iv) into syngeneic recipient mice which differ in the lymphocyte marker allele ( CD45.1 on transgenic cells or CD45.2 on cells of the recipient mice.)
  • the activation or expansion of the specific (CD45.1-positive) CTL can be followed.
  • mice The following mice were used:
  • an imiquimod-containing cream (Aldara R 5%, company 3M) was used.
  • the peptide SGPSNTPPEI from the E1A protein of adenovirus type 5 was synthesized by PD Dr. med. Stefan Stevanovic, Institute of Cell Biology, Dept. Immunology, University of Tübingen.
  • mice were killed; the spleen was removed, treated with 5 ml of phosphate buffered saline solution (PBS) and crushed with the punch of a 5 ml syringe in a 70 ⁇ m nylon mesh over a 50 ml tube.
  • the cells were rinsed into the tube with an additional 5 ml of PBS and centrifuged off (1500 rpm, 3 min).
  • the cell pellet was resuspended in 5 ml of ice-cold ACK buffer (150 mM NH 4 Cl, 1 mM KHCO 3 , 0.1 mM EDTA, pH 7.3) and incubated for 5 min at RT.
  • the cells were spun down and washed once with PBS.
  • the cells were counted using a Neubauer counting chamber and resuspended at 12 x 10 6 cells per ml in PBS.
  • spleen suspension 250 ⁇ l of the spleen suspension (equivalent to 3 ⁇ 10 6 cells) were drawn into a 1 ml syringe and stored on ice until injection. The recipient mice were clamped in a holder and the cell suspension was injected intravenously into the tail vein.
  • mice were shaved under anesthesia (Metofane, Janssen-Cilag company) so that a bald spot of about 10 cm 2 was formed.
  • anesthesia Metalofane, Janssen-Cilag company
  • the mice were bled with 50 mg of TLR7 ligand ("imiquimod") cream (Aldera R , company 3M) and the synthetic peptide SGP (stock solution: 10 ⁇ g / ml in DMSO)
  • the immunization was repeated after 24 h.
  • mice were shaved under anesthesia (Metofane, Janssen-Cilag company) so that a bald spot of about 10 cm 2 was formed.
  • anesthesia Metalofane, Janssen-Cilag company
  • the mice were first injected under anesthetic with peptide (diluted from the DMSO stock solution to 250 ⁇ l in PBS) intradermally.
  • the back of the mice was creamed with 50 mg of TLR7 ligand ("imiquimod") cream (Aldera R , company 3M)
  • the application of the cream was repeated after 24 h.
  • CTL cytotoxic T cells
  • mice were bled from the tail vein 4 days after the last immunization, and the blood sample was analyzed by flow cytometry.
  • the erythrocytes were lysed in ACK buffer.
  • the remaining cells were taken up in FACS buffer (0.5% bovine serum albumin (BSA), 2 mM EDTA, sodium azide in PBS) and washed once in FACS buffer.
  • BSA bovine serum albumin
  • the specific cytotoxic functionality of the activated cells was determined by means of a so-called / n-wVo killer assay 6 days after the last immunization.
  • spleen cells from syngeneic mice labeled with CFSE (5,6-carboxyfluorescein diacetate-succinimidyl ester, Molecular Probes) were used as target cells for the cytotoxic T cells (CTLs).
  • CTLs cytotoxic T cells
  • the labeled with 3 uM CFSE cells were treated with the artificial SGP-peptide loaded (10 uM peptide; 40 x 10 6 cells per ml medium ISC; 1 h; 37 0 C), and that the wur ⁇ then washed twice with medium and washed twice washed with PBS.
  • the 0.3 ⁇ M CFSE-labeled cells were incubated only in ISC medium and also washed.
  • the cells were mixed at a 1: 1 ratio and 15 x 10 6 cells in 300 ⁇ l each of PBS iv were injected into the mice. After 18 hours, the mice were sacrificed and the spleen cells were removed and analyzed by flow cytometry.
  • the preparation of the spleen cells was carried out as described above. After ACK lysis, the cells were resuspended in 10 ml PBS, counted and adjusted to 2 x 10 7 cells per ml. The cell suspension was mixed with an adequate Volu ⁇ men a 6 uM and 0.6 uM CFSE solution mixed (in PBS) and incubated for 4 min at 37 0 C. The reaction was then stopped by adding twice the volume of ISC medium supplemented with 10% fetal calf serum (FCS). The cells were washed twice with FCS-free medium and counted.
  • FCS fetal calf serum
  • TCR transgenic cytotoxic T cells were administered i.v. injected into congenucent recipient mice and immunized with their specific MHC class I ligand. The results are shown in Figure 1 ( Figure 1: Proliferation (A) and functionality (B) of transcutaneously activated transgenic cytotoxic T cells).
  • the proportion of transgenic CD8 + cells in the total population of CD8 + cells was determined by flow cytometry in blood or spleen.
  • the lymphocytes were stained with the antibodies anti-CD8 APC-Cy7-conjugated, anti-CD45.1 PE-conjugated (commercially available from Becton-Dickinson Pharmingen, Hamburg).
  • the fluorescence in the FL-2 channel (PE) of the CD8 + lymphocytes can be seen in each case.
  • the proportion of CD45.1 + cells is given in percent in the respective histograms. In all mice, the proportion of transgenic CD8 + cells was determined before the immunization and 4 days after immunization in the spleen (A).
  • an in vivo WVO killer assay was performed 6 days after immunization.
  • syngeneic spleen cells labeled with high CFSE concentration were loaded with peptide, mixed 1: 1 with non-peptide, weaker CFSE-labeled cells and transferred iv into the mice.
  • the spleens of the mice were removed and the number of CFSE-labeled cell populations was compared.
  • a decrease in the number of peptide-loaded cells indicated a specific lysis of the activated CTLs.
  • the fluorescence of the spleen cells in the FL-1 channel (CFSE) is shown in each case. The lysis was calculated on the number of unloaded cells and is expressed as a percentage (B).
  • the peptide is administered alone (without additives, adjuvants), only a marginal increase in transgenic cells takes place.
  • These activated CTL can also be detected as a lymphoid organ on day 6 in the spleen. This indicates that a systemic activation of the CTL has taken place, which shows that in addition to the specific peptide, an adjuvant (CFA, imiquimod) is additionally required for the activation of the TCR transgenic CTL.
  • CFA Toll-like receptor ligand
  • Group # 2 50 ⁇ g peptide (id) + imiquimod cream (ed)
  • Group # 3 50 ⁇ g peptide (id)
  • Group # 4 100 ⁇ g peptide + imiquimod cream (ed)
  • Group # 5 20 ⁇ g peptide + imiquimod cream (ed)
  • transgenic CTLs were transferred to recipient mice and these were compared to the TLR Treated ligands (imiquimod) containing preparation which contained or did not contain the peptide. As shown in FIG.
  • FIG. 2 shows the functionality of transcutaneously activated transgenic cytotoxic T cells.
  • a ⁇ -wVo killer assay was performed 6 days after immunization.
  • syngeneic spleen cells labeled with high CFSE concentration were loaded with peptide, mixed with non-peptide, weaker CFSE-labeled cells in a ratio of 1: 1 and transferred iv into the mice.
  • the spleens of the mice were removed and the cell number of the two labeled CFSE-labeled cell populations was compared.
  • a decrease in the number of peptide-loaded cells indicates specific lysis of the activated CTLs.
  • the fluorescence of the spleen cells in the FL1 channel (CFSE) can be seen in each case.
  • the Specific lysis was calculated on the number of unloaded cells and is expressed as a percentage.
  • the pharmaceutical preparations according to the invention and their use, as well as the processes according to the invention, show that it is possible to activate antigen-specific cytotoxic T cells, which are then also functional.
  • Prerequisites for the functionality are on the one hand the presence of APC in the skin, which can present an MHC class I ligand, and on the other hand knowledge of the exact structure of the MHC molecules and the antigen to be immunized against.
  • no injections are required, which considerably simplifies the process and makes pharmaceutical preparations considerably more cost-effective for its use.
  • the present invention thus relates to a pharmaceutical preparation which comprises at least one toll-like receptor ligand, at least one peptide and optionally one or more substance (s) from the group carriers, excipients and additives.
  • the invention relates to a pharmi ⁇ cal preparation according to the above definition, wherein the at least one Toll-like receptor ligand is selected from the group consisting of TLR2 ligand, TLR3 ligand, TLR7 ligand, TLR8 ligand and TLR9 ligand, preferably in which the at least one Toll-like receptor ligand is a TLR7 ligand.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to the preceding definition, wherein the at least one Toll-like receptor ligand is selected from the group consisting of compounds of natural and / or synthetic origin, which is derived from at least one like receptors are recognized and for triggering one or more of the immune response-promoting signals (s) are useful, preferably wherein the at least one Toll-like receptor ligand is selected from the group consisting of Pam3Cys, poly (I: C), imiquimod, loxoribine, R-848 and CpG DNA, more preferably wherein the Toll-like receptor ligand Imiquimod is.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to one of the above definitions, wherein the at least one peptide is selected from Major histocompatibility complex class I ligand, major histocompatibility complex class II ligand and other peptides containing these ligands ,
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to one of the above definitions which has at least one Toll-like receptor ligand in an amount of from 0.1 to 10% by weight; at least one peptide in an amount of 0.01 to 30% by weight; and one or more substance (s) from the group carriers, excipients and additives in a total amount of 0.1 to 99.9 wt .-%, each based on the total weight of the pharmaceutical preparation comprises.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to one of the above definitions, which comprises at least one synthetic Toll-like receptor ligand and the at least one synthetic peptide in a formulation for common administration and action.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to one of the above definitions, which comprises the at least one synthetic Toll-like receptor ligand and the at least one synthetic peptide in separate formulations for separate administration and joint action.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to one of the above definitions in a formulation suitable for topical administration.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation according to one of the above definitions in a for the topical administration of a component and for the non-topical, preferably the subcutaneous or intradermal administration of another component with the aim of the common Effect appropriate formulation.
  • a further preferred embodiment of the invention relates to a pharmaceutical preparation as defined above in a topical administration of at least one Toll-like receptor ligand and a non-topical, preferably subcutaneous or intradermal administration of at least one synthetic peptide with the Aim of the common action suitable formulation.
  • the present invention also relates to the use of a pharmaceutical preparation according to one of the above definitions for the prophylaxis and / or treatment of diseases induced by viruses and / or bacteria and / or fungi in a mammal.
  • the present invention also relates to the use of a pharmaceutical preparation according to one of the above definitions for the prophylaxis and / or treatment of diseases caused by excessive cell proliferation in a mammal.
  • the present invention further relates to the use of a pharmaceutical preparation according to one of the above definitions for the production of a medicament for the prophylaxis and / or therapy of diseases induced by viruses and / or bacteria and / or fungi in a mammal.
  • the present invention further relates to the use of a pharmaceutical preparation according to one of the above definitions for the production of a medicament for the prophylaxis and / or therapy of diseases caused by excessive cell proliferation in a mammal.
  • a preferred embodiment of the invention relates to the use of any of the above definitions, wherein the mammal is a human.
  • a further preferred embodiment of the invention relates to the use according to one of the above definitions by way of topical application of the pharmaceutical preparation, preferably by way of the application of the pharmaceutical preparation to the skin of the mammal.
  • a further preferred embodiment of the invention relates to the use according to one of the above definitions by way of the separate topical application of one component and non-topical, preferably subcutaneous or intradermal, application of another component with the aim of a joint action, preferably by way of topical application of a component to the skin of the mammal and the subcutaneous or intradermal administration of another component which takes place temporally immediately before or after or simultaneously with the topical application.
  • a further preferred embodiment of the invention relates to the use according to the above definition by means of the separate topical application of a formulation comprising at least one Toll-like receptor ligand and subcutaneous or intradermal administration of a formulation comprising at least one synthetic peptide Aim of the common effect.
  • the present invention also relates to a method for the prophylaxis and / or therapy of diseases induced by viruses and / or bacteria and / or fungi. in a mammal comprising the administration of a pharmaceutical preparation according to one of the above definitions to the mammal in a concentration of the pharmacologically active components effective for the prophylaxis and / or therapy of said diseases.
  • the present invention also relates to a method for the prophylaxis and / or treatment of diseases caused by excessive cell proliferation in a mammal, which comprises administering to the mammal a pharmaceutical preparation according to one of the above definitions in a prophylaxis and / or therapy said diseases comprises effective concentration of the pharmacologically active components.
  • the present invention also relates to a method for the prophylactic and / or therapeutic activation of the adaptive immune system of a mammal, which comprises administering to the mammal a pharmaceutical preparation according to any of the above definitions for prophylactic and / or therapeutic activation of the immune system of the mammal effective concentration of the pharmacologically active components.
  • the present invention further relates to a method for the prophylactic and / or therapeutic activation of cytotoxic T cells of the immune system of a mammal, which comprises administering a pharmaceutical preparation according to one of the above definitions to the mammal in a prophylactic and / or therapeutic Activation of the cytotoxic T cells effective concentration of pharmacologically active components um ⁇ sums
  • a preferred embodiment of the invention relates to a method according to one of the above definitions, wherein the mammal is a human.
  • a further preferred embodiment of the invention relates to a method according to one of the above definitions, wherein the administration of the pharmaceutical preparation is carried out by topical route, preferably in which the pharmaceutical preparation is applied to the skin of the mammal.
  • a further preferred embodiment of the invention relates to a method according to one of the above definitions, wherein the administration of a part of the pharmaceutical preparation with one component takes place by topical route and the administration of another part of the pharmaceutical preparation with another component to non-topical, preferably by subcutaneous or intradermal routes with the aim of a common action, more preferably wherein the administration of a part of the pharmaceutical preparation with a component is carried out by application to the skin of the mammal and the administration of another part of the pharmaceutical preparation is effected with another component by subcutaneous or intradermal administration to the mammal with the aim of the common action taking place immediately before or after or simultaneously with the application to the skin.
  • the invention relates to a method according to the above definition, wherein the administration of a portion of the preparation comprising at least one Toll-like receptor ligand by topical application to the skin and the administration ei ⁇ another part of the preparation comprising at least one peptide is by subcutaneous or intradermal administration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une préparation pharmaceutique contenant au moins un ligand du récepteur de type Toll et au moins un peptide. L'invention concerne également l'utilisation d'une préparation pharmaceutique de ce type, ainsi qu'un procédé de vaccination.
EP05797932A 2004-10-08 2005-10-06 Des adjuvants pour la vaccination etant le pam3cys, poly(i:c), imiquimod, loxoribine, r-848 et le cpg-dna, combine avec des epitopes du chm i ou chm ii Ceased EP1846029A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200410049223 DE102004049223A1 (de) 2004-10-08 2004-10-08 Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
PCT/EP2005/010785 WO2006040076A2 (fr) 2004-10-08 2005-10-06 Preparation de vaccination, procede de vaccination et utilisation d'une preparation de vaccination

Publications (1)

Publication Number Publication Date
EP1846029A2 true EP1846029A2 (fr) 2007-10-24

Family

ID=35613670

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05797932A Ceased EP1846029A2 (fr) 2004-10-08 2005-10-06 Des adjuvants pour la vaccination etant le pam3cys, poly(i:c), imiquimod, loxoribine, r-848 et le cpg-dna, combine avec des epitopes du chm i ou chm ii

Country Status (5)

Country Link
US (1) US9017654B2 (fr)
EP (1) EP1846029A2 (fr)
CA (1) CA2582662C (fr)
DE (1) DE102004049223A1 (fr)
WO (1) WO2006040076A2 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008527009A (ja) 2005-01-19 2008-07-24 バクシネート コーポレーション 病原体関連分子パターンおよび抗原を含む組成物ならびに免疫応答を刺激するためのそれらの使用
WO2007078879A2 (fr) * 2005-12-21 2007-07-12 Vaxinnate Corporation Compositions de lipopeptides et leurs procédés d'utilisation
EP2476432B1 (fr) 2006-03-07 2015-08-19 Vaxinnate Corporation Compositions incluant de l'hémagglutinine, procédés pour leur fabrication et leurs méthodes d'utilisation
KR100900837B1 (ko) * 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
SG190562A1 (en) 2008-04-18 2013-06-28 Vaxinnate Corp Deletion mutants of flagellin and methods of use
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
DK2378876T3 (en) 2008-12-19 2019-03-11 Medicis Pharmaceutical Corp IMIQUIMOD FORMULATIONS WITH LOWER DOSAGE STRENGTH AND SHORT-TERM DOSAGE PLAN FOR TREATMENT OF ACTINIC KERATOSIS
GEP20156418B (en) 2009-07-13 2016-01-11 Medicis Pharmaceutical Corp Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts
US8303840B2 (en) 2010-03-12 2012-11-06 The Gillette Company Acid-treated manganese dioxide and methods of making thereof
US8298706B2 (en) 2010-03-12 2012-10-30 The Gillette Company Primary alkaline battery
US20110219607A1 (en) * 2010-03-12 2011-09-15 Nanjundaswamy Kirakodu S Cathode active materials and method of making thereof
US20110223477A1 (en) * 2010-03-12 2011-09-15 Nelson Jennifer A Alkaline battery including lambda-manganese dioxide and method of making thereof
DE102011018499A1 (de) 2011-04-23 2012-10-25 Emc Microcollections Gmbh Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
IN2014CN04251A (fr) * 2011-11-09 2015-07-17 Ascend Biopharmaceuticals Ltd
US9570741B2 (en) 2012-03-21 2017-02-14 Duracell U.S. Operations, Inc. Metal-doped nickel oxide active materials
US9028564B2 (en) 2012-03-21 2015-05-12 The Gillette Company Methods of making metal-doped nickel oxide active materials
US8703336B2 (en) 2012-03-21 2014-04-22 The Gillette Company Metal-doped nickel oxide active materials
US8932598B2 (en) 2012-08-28 2015-01-13 Vaxinnate Corporation Fusion proteins and methods of use
IN2014CH00393A (fr) * 2013-02-05 2015-04-03 Nitto Denko Corp
EP2762155B1 (fr) 2013-02-05 2020-03-11 Nitto Denko Corporation Composition vaccinale
JP6497691B2 (ja) 2013-02-05 2019-04-10 日東電工株式会社 粘膜投与用ｗｔ１ペプチド癌ワクチン組成物
KR20140100415A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
KR20140100417A (ko) 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 투여용 백신 조성물
CA2840978A1 (fr) 2013-02-05 2014-08-05 Nitto Denko Corporation Composition de vaccin pour administration muqueuse
CN103961698A (zh) 2013-02-05 2014-08-06 日东电工株式会社 经皮或粘膜给予用疫苗组合物
KR20140099828A (ko) 2013-02-05 2014-08-13 닛토덴코 가부시키가이샤 점막 투여용 백신 조성물
RU2685933C2 (ru) 2013-02-05 2019-04-23 Нитто Денко Корпорейшн Композиция противораковой вакцины, содержащая пептид wt1, для трансдермального введения
US10449144B2 (en) 2013-02-05 2019-10-22 Nitto Denko Corporation WT1 peptide cancer vaccine composition for transdermal administration
US9793542B2 (en) 2014-03-28 2017-10-17 Duracell U.S. Operations, Inc. Beta-delithiated layered nickel oxide electrochemically active cathode material and a battery including said material
CN106687138B (zh) 2014-09-03 2021-10-15 日东电工株式会社 包含双膦酸盐剂的细胞性免疫用疫苗药物组合物
US10471141B2 (en) 2014-09-03 2019-11-12 Nitto Denko Corporation Bisphosphonate-containing vaccine pharmaceutical composition for humoral immunity
EP3332809A4 (fr) * 2015-08-06 2019-04-10 Nitto Denko Corporation Composition favorisant l'induction d'immunité et composition pharmaceutique de vaccin
AU2018266709B2 (en) 2017-05-09 2023-01-05 Duracell U.S. Operations, Inc. Battery including beta-delithiated layered nickel oxide electrochemically active cathode material
EP3646882A1 (fr) 2018-11-05 2020-05-06 Universitätsmedizin der Johannes Gutenberg-Universität Mainz Compositions pharmaceutiques, vaccins et leurs utilisations dans la prévention ou le traitement d'une infection persistante ou du cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5662907A (en) 1992-08-07 1997-09-02 Cytel Corporation Induction of anti-tumor cytotoxic T lymphocytes in humans using synthetic peptide epitopes
US20020058674A1 (en) 1999-01-08 2002-05-16 Hedenstrom John C. Systems and methods for treating a mucosal surface
SK287112B6 (sk) 1999-01-08 2009-12-07 3M Innovative Properties Company Použitie zlúčeniny modifikujúcej imunitnú odpoveď pri liečení cervikálnej dysplázie
US6486168B1 (en) 1999-01-08 2002-11-26 3M Innovative Properties Company Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6147086A (en) 1999-09-01 2000-11-14 Brenman; Steven A. Method employing imiquimod cream for treatment of topical sarcoidosis on equine
GB0023008D0 (en) 2000-09-20 2000-11-01 Glaxo Group Ltd Improvements in vaccination
ATE536187T1 (de) 2000-10-19 2011-12-15 Epimmune Inc Hla-klasse-i- und -klasse-ii-bindende peptide und ihre verwendungen
EP1390495B1 (fr) 2001-05-21 2007-07-04 Intercell AG Molécules oligodésoxynucléiques immunostimulatrices
JP4601956B2 (ja) 2001-09-20 2010-12-22 グラクソ グループ リミテッド Ｈｉｖ−ｇａｇのコドン最適化ｄｎａワクチン
US20030185835A1 (en) * 2002-03-19 2003-10-02 Braun Ralph P. Adjuvant for vaccines
AU2003216851B2 (en) 2002-03-19 2008-04-17 Powderject Research Limited Imidazoquinoline adjuvants for vaccines
DK1545597T3 (da) * 2002-08-15 2011-01-31 3M Innovative Properties Co Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
EP1550458A1 (fr) 2003-12-23 2005-07-06 Vectron Therapeutics AG Adjuvants liposomals synergiques

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BEIGNON ANNE-SOPHIE ET AL: "Immunization onto bare skin with synthetic peptides: Immunomodulation with a CpG-containing oligodeoxynucleotide and effective priming of influenza virus-specific CD4+ T cells", IMMUNOLOGY, vol. 105, no. 2, February 2002 (2002-02-01), pages 204 - 212, ISSN: 0019-2805 *
KOELLISCH G V ET AL: "Evidence for functional expression of Toll-like receptors (TLRs) in human keratinocytes.", ARCHIVES OF DERMATOLOGICAL RESEARCH, vol. 295, no. 8-9, February 2004 (2004-02-01), & 31ST ANNUAL MEETING OF THE ARBEITSGEMEINSCHAFT DERMATOLOGISCHE FORSCHUNG IN COOPERATION WITH THE DEU; BERLIN, GERMANY; FEBRUARY 26-28, 2004, pages 347, ISSN: 0340-3696 *
ZUBER A K ET AL: "Topical delivery of imiquimod to a mouse model as a novel adjuvant for human immunodeficiency virus (HIV) DNA", VACCINE, ELSEVIER LTD, GB, vol. 22, no. 13-14, 16 April 2004 (2004-04-16), pages 1791 - 1798, XP004500434, ISSN: 0264-410X, DOI: DOI:10.1016/J.VACCINE.2003.10.051 *

Also Published As

Publication number Publication date
WO2006040076A2 (fr) 2006-04-20
US9017654B2 (en) 2015-04-28
DE102004049223A1 (de) 2006-04-20
CA2582662A1 (fr) 2006-04-20
CA2582662C (fr) 2015-06-02
WO2006040076A3 (fr) 2006-09-08
US20080193487A1 (en) 2008-08-14

Similar Documents

Publication Publication Date Title
EP1846029A2 (fr) Des adjuvants pour la vaccination etant le pam3cys, poly(i:c), imiquimod, loxoribine, r-848 et le cpg-dna, combine avec des epitopes du chm i ou chm ii
DE69225710T2 (de) Anregung von antworten zytotoxischer t-lymphozyten
DE69836643T2 (de) Zusammensetzungen für die zufuhr von genen an antigen-präsentierende zellen der haut
DE69935507T2 (de) Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
DE69826288T2 (de) Zelluläres vesikel 'exosome', seine herstellung und verwendung zur stimulierung einer immunantwort
DE69733145T2 (de) Verfahren zur behandlung von allergischen lungenkrankheiten
DE69329344T2 (de) Spezifische modulationen des immunsystems
DE69839273T2 (de) Krebsimmuntherapie mit semi-allogenen zellen
KR101819688B1 (ko) 변형된 면역-조절 입자
JP6348489B2 (ja) カチオン性脂質ワクチン組成物および使用方法
ES2320971T3 (es) Arqueosomas como adjuvantes y vehiculos para vacunas acelulares para inducir respuestas de linfocitos t cototoxicos.
DE69014543T2 (de) Multivalentes immunogen lmi.
DE69838324T2 (de) Ph-sensitive liposomen und andere typen immunomodulatoren enthaltender gekapselter impfstoffe sowie herstellungs- und anwendungsverfahren dafür
WO2018045199A2 (fr) Complexes de capsules peptidiques-acides nucléiques
EP1308167A1 (fr) Vésicles présentatrices d'antigène
DE102011018499A1 (de) Topische Nanopartikel-Vakzine zur Immunstimulation der dendritischen Zellen in der Haut
DE69633919T2 (de) Mehrzweckvakzine gegen umhüllte viren
AT412145B (de) Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
WO2000012122A2 (fr) Fragments de l'acide hyaluronique de faible poids moleculaire pour la preparation de vaccins
DE69428984T2 (de) Stimulierung der immunantwort durch virales protein
WO2012055551A2 (fr) CELLULES DENDRITIQUES À VOIE DE SIGNALISATION NFĸB MANIPULÉE
EP1071411B1 (fr) Immunostimulation topique visant a induire la migration des cellules de langerhans
DE69926342T2 (de) Lieferung von immunogenen molekülen unter verwendung von hbsag partikeln
EP1727563A1 (fr) Procede pour amplifier l'activite de vaccins therapeutiques
WO2013103362A1 (fr) Plaquettes présentant un antigène et méthodes visant à induire une réponse immune

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070508

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20080122

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20110513